HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At Nuvothera, Rx Derma Veterans Develop OTCs For Serious Skin Conditions

Executive Summary

Firm launched Prosoria in 2018 as a four-product topical line for inflammatory autoimmune disease psoriasis containing salicylic acid 3% combined with turmeric and other botanicals. CEO Arthur Clapp says firm will launch turmeric supplements and plans adding products for acne, eczema, warts, nail fungus and rosacea.

You may also be interested in...



Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.

Tests Show CBD Levels In Some Supplements Don't Match Labeling

Seven of 10 CBD-containing supplement products tested in a lab did not contain the levels of CBD advertised on the label, says hemp, CBD and natural health product information publisher Remedy Reviews. Most products also were found to contain heavy metals.

P&G Advertising ‘Reinvention’ Produces SK-II Videos Capturing 661M Views

P&G approach to advertising for SK-II skin care drove double-digit sales growth in new users and prompted a 27% increase in searches for the line. P&G has saved $1bn from cost-cutting in ad agencies and advertising implemented over past five years, says chief brand officer Marc Pritchard.

Topics

Related Companies

UsernamePublicRestriction

Register

RS148540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel